Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.

James Yan-Yue FungTiffany WongKenneth Siu-Ho ChokAlbert ChanTan-To CheungJeff Wing-Chiu DaiSui-Ling SinKa-Wing MaKelvin NgKevin Tak-Pan NgWai Kay SetoChing-Lung LaiMan Fung Yuen Chung Mau Lo

Published in: Hepatology (Baltimore, Md.) (2017)

Long-term entecavir monotherapy is highly effective at preventing HBV reactivation after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance rate of 92%, an undetectable HBV DNA rate of 100% at 8 years, and excellent long-term survival of 85% at 9 years. (Hepatology 2017;66:1036-1044).

Keyphrases

hepatitis b virus
liver failure
combination therapy
open label
randomized controlled trial
clinical trial
single molecule
nucleic acid